Certara (NASDAQ:CERT) Receives Equal Weight Rating from Barclays

Barclays reaffirmed their equal weight rating on shares of Certara (NASDAQ:CERT) in a research report sent to investors on Friday, Marketbeat.com reports. The firm currently has a $8.00 price objective on the stock.

CERT has been the topic of several other reports. Rothschild & Co Redburn set a $10.00 price objective on shares of Certara in a research note on Friday, November 21st. Leerink Partners reissued an “outperform” rating and set a $10.00 price target on shares of Certara in a research report on Thursday, February 26th. KeyCorp dropped their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Finally, Stephens reduced their target price on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and an average target price of $11.10.

Certara Stock Down 1.3%

Shares of NASDAQ:CERT traded down $0.09 during trading on Friday, hitting $7.06. 2,441,235 shares of the company were exchanged, compared to its average volume of 3,293,182. Certara has a fifty-two week low of $6.04 and a fifty-two week high of $15.38. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -706.00 and a beta of 1.50. The company has a current ratio of 2.05, a quick ratio of 2.05 and a debt-to-equity ratio of 0.27. The firm has a fifty day moving average price of $8.18 and a two-hundred day moving average price of $9.76.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The firm had revenue of $103.65 million during the quarter, compared to the consensus estimate of $103.23 million. During the same period in the prior year, the business posted $0.15 earnings per share. Certara’s quarterly revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, research analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

Several hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its position in shares of Certara by 580,097.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock valued at $7,310,000 after purchasing an additional 829,540 shares during the last quarter. Corient Private Wealth LLC acquired a new position in shares of Certara in the fourth quarter valued at about $111,000. nVerses Capital LLC bought a new position in Certara during the fourth quarter worth about $184,000. Toronto Dominion Bank raised its stake in Certara by 186.9% in the 4th quarter. Toronto Dominion Bank now owns 83,939 shares of the company’s stock worth $739,000 after purchasing an additional 54,677 shares in the last quarter. Finally, Oxford Asset Management LLP acquired a new stake in Certara in the 4th quarter worth about $256,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.